BioMedNewsBreaks

TuesdayJan 05, 2021 11:30 am

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Engages Investor Relations Firm

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that it has hired an investor relations firm. POAI has chosen Landon Capital to provide investor relations services; the agreement was effective Dec. 30, 2020. The announcement noted that anticipated services would include introductions to investors, financial and industry analysts, registered brokers and financial writers. Those introductions would be made with the intent to provide interested individuals and groups with information about POAI’s business strategy, developments and accomplishments. The announcement also noted that Landon Capital would assist POAI in the…

Continue Reading

TuesdayJan 05, 2021 10:39 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Enters into Agreement with Fortune 500 Subsidiary to Provide Digital Therapeutics Solution

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has been selected by a subsidiary of a U.S.-based Fortune 500 technology and engineering company to provide its digital therapeutics solution to eligible employees. DarioHealth’s partnership with Vitality Group made this agreement possible, which is DarioHealth’s first client in the self-insured employer market. One of the largest wellness companies in the world, Vitality Group blends industry-leading smart tech, data, incentives and behavioral science to inspire healthy changes in individuals and their organizations; an estimated 20 million people in 26 markets engage in the Vitality program. Under the announced agreement, members…

Continue Reading

TuesdayJan 05, 2021 10:05 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Participation in LifeSci Partners Corporate Access Event

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, will be participating in the 10th annual LifeSci Partners Corporate Access Event. As part of the company’s participation, AzurRx president and CEO James Sapirstein will present a summary of the company’s business and clinical-development programs to any interested parties. His presentation will also include expected 2021 highlights. In addition, Sapirstein will participate in virtual one-on-one meetings with registered investors and pharmaceutical companies. The multiday event is scheduled for Jan. 6–8 and 11–14, 2021. To register for the event, visit https://ibn.fm/JBmMH To view the full press release, visit…

Continue Reading

MondayJan 04, 2021 2:34 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Shares Objectives for Berubicin Phase 2 Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently hosted a webinar to discuss the clinical design for its upcoming Phase 2 trial. The trial will study its lead drug candidate, Berubicin, for the treatment of glioblastoma multiforme (“GBM”), an aggressive form of brain cancer currently considered incurable. Berubicin is an anthracycline that has demonstrated significant potential to effectively cross the blood-brain barrier and target central nervous system malignancies. The company’s Phase 2 trial will recruit 243 patients for side-by-side, real-time analysis…

Continue Reading

MondayJan 04, 2021 2:02 pm

BioMedNewsBreaks – Retractable Technologies Inc. (NYSE: RVP) Named ‘2020’s Stock of the Year’ by The Bowser Report

Retractable (NYSE: RVP), a manufacturer and marketer of safety syringes and other innovative medical products for the health care industry, was recognized as the “Stock of the Year” for 2020 by The Bowser Report LLC. The report reads, “Unlike last year’s top pick [Repro Med Systems Inc. (NASDAQ: KRMD)], Retractable Technologies is a recent addition to the newsletter, named Company of the Month in January 2020. At the time, RVP was trading at $1.48. Just a couple of months after recommendation, the world and financial markets were shocked by the COVID-19 pandemic, which forced lockdowns, quarantines and stay-at-home orders. While…

Continue Reading

MondayJan 04, 2021 12:02 pm

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Worldwide License Agreement with First Wave Bio, $8M Offerings

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal (“GI”) diseases, today announced its entry into an exclusive worldwide licensing agreement with First Wave Bio Inc. for the use of its patented and proprietary oral and rectal formulations of niclosamide for the treatment of immune checkpoint inhibitor-associated colitis (“ICI-AC”) and COVID-19 GI infections. “The acquisition of rights to niclosamide for these indications gives us an opportunity to strategically expand our existing pipeline and pursue multiple GI indications in the oncology and infectious disease arenas,” said James Sapirstein, president and CEO of AzurRx. “We are…

Continue Reading

ThursdayDec 31, 2020 3:18 pm

BioMedNewsBreaks – Why United Medical Equipment Business Solutions Network Inc. Is ‘One to Watch’

United Medical Equipment (“UME”) is a provider of reliable resources and solutions to fit the ever-changing needs of an aging population that includes seniors and veterans, as well as those impacted by the COVID-19 pandemic. The company is uniquely poised to offer health care across the continuum of care with solutions that help providers work more proficiently, health care systems work smarter, and patients live healthier lives. UME operates nationwide with a corporate office located in Fort Worth, Texas. A recent article discussing the company reads, “United Medical Equipment provides services that have been thoroughly vetted, have a good reputation,…

Continue Reading

ThursdayDec 31, 2020 2:56 pm

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Eyes Expansion of Proprietary Imaging Technology

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, assists surgeons to more effectively root out cancers in a minimally invasive manner by making it possible to better see the interior recesses of men and women during medical procedures. The company will launch its platform with the introduction of the i/Blue Imaging (TM) System, a proprietary imaging technology based on advanced optics and light sensors. The value of Imagin’s platform is that it makes surgery-revolutionizing technology more available to hospitals through the ability to adapt it to existing equipment. A recent article discussing Imagin’s solution reads, “The company’s initial…

Continue Reading

WednesdayDec 30, 2020 3:11 pm

BioMedNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Secures Patent for Natural Biopesticide Treatment of Stored Produce, Foods

MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural biological protection for high value crops, was recently granted an exclusive patent licensing from the University of Idaho in Moscow, Idaho (https://ibn.fm/EF2NV). According to the update, the patent is in connection with a natural biopesticide mustard-based treatment of stored produce and other foods. The treatment’s potential for sprout suppression of potatoes seems optimally timed, particularly amid increased interest in alternatives to chlorpropham (“CIPC”). The leading agrochemical product used for sprout suppression, CIPC is a critical element of potato storage. However, there are growing regulations to…

Continue Reading

WednesdayDec 30, 2020 11:09 am

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Publication Detailing Its Investigational Neuropharmaceuticals for Anxiety and Depression Disorders

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that VistaGen Vice President, Translational Medicine Dr. Louis Monti and VistaGen CNS Clinical and Regulatory Advisory Board Member Dr. Michael Liebowitz authored an article published in CNS Spectrums, a Cambridge University Press journal. The article covers the proposed mechanism of action of VistaGen’s investigational neuroactive nasal sprays, PH94B and PH10, currently in development as potential rapid-onset treatments for anxiety and depression disorders.* The publication details the proposed neural circuits mediating the mechanism of action of pherines, including PH94B…

Continue Reading